Biostax Corp. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-02-20: Form 8-K; Period of report 2025-02-19; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 7.01 Regulation FD Disclosure; Details 3.01.
- 2023-11-14: Form 8-K; Period of report 2023-11-08; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 5.02.
- 2023-11-02: Form 8-K; Period of report 2023-10-24; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 5.02.
- 2023-10-24: Form 8-K; Period of report 2023-10-05; Description 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events; Details 5.03.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2025-02-20 | 8-K | 2025-02-19 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 7.01 Regulation FD Disclosure | 3.01 On February 19, 2025, Biostax Corp (the "Company") notified the Securities and Exchange Commission (the "SEC") of the Company's intention to voluntarily file a Form 25 (Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934). 7.01 On October 6, 2024, the Company issued a press release announcing its intention to voluntarily delist from the OTC Pink marketplace and deregister its common stock. | biox-20250219.htm |
| 2023-11-14 | 8-K | 2023-11-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 Appointment of Roger Craig Suro as Director On November 8, 2023 the board of directors of Biostax Corp, (the “Company”) appointed Mr. Roger Craig Suro, age 49 to the Board of Directors in accordance with the bylaws of the Issuer. 8.01 On November 15, 2023 Biostax Corp (the “Company”) issued a press release announcing the appointment of Mr. Roger Craig Suro to the Board of Directors. | form8-k.htm |
| 2023-11-02 | 8-K | 2023-10-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 Appointment of Clay Caperton Renyolds as Director On October 24, 2023 the board of directors of Biostax Corp, (the “Company”) appointed Ms. Mary Clay Caperton, age 61 to the Board of Directors in accordance with the bylaws of the Issuer. 8.01 On November 2, 2023 Biostax Corp (the “Company”) issued a press release announcing the appointment of Ms. Mary Clay Caperton to its Board of Directors. | form8-k.htm |
| 2023-10-24 | 8-K | 2023-10-05 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 5.03 On October 5, 2023, Immune Therapeutics, Inc. d/b/a Biostax Corp (the “Company”) filed a Articles of Amendment to the Articles of Incorporation (“Amendment”) with the Secretary of State of the State of Florda to change its corporate name from Immune Therapeutics, Inc. to Biostax Corp., effective October 5, 2023. 8.01 On Oct 24, 2023 the Company issued a press release announcing the name change approval, the new ticker and its dedication to advancing HIV treatments and international substance abuse. | form8-k.htm |
| 2023-09-14 | 8-K | 2023-09-14 | 7.01 Regulation FD Disclosure | 7.01 On September 14, 2023, Immune Therapeutics, Inc. d/b/a Biostax Corp. (the “Company”) issued a press release announcing that Henry Louis Salomonsky, a director of the Company, died on August 31, 2023, and that the Company would be seeking to fill the vacancy on the board of directors of the Company left by Mr. Salomonsky. | form8-k.htm |
| 2023-09-13 | 8-K | 2023-09-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 25, 2023, Robert Wilson, President and director of Immune Therapeutics, Inc. d/b/a Biostax Corp. (the “Company”), delivered a letter of resignation to the Company, pursuant to which Mr. Wilson resigned as President of the Company, effective immediately. | form8-k.htm |
| 2023-04-20 | 8-K | 2023-04-20 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 5.02 On April 12, 2023, the Board of Directors of the Company (the “Board”) appointed Kelly O. Wilson, the Company’s current Chief Operating Officer, Interim President, and Interim Chief Executive Officer, as the Company’s Chief Executive Officer. 8.01 On April 20, 2023, the Company issued a press release announcing the Settlement Agreement with Statera as well as Licensing Amendment. | form8-k.htm |
| 2023-03-06 | 8-K | 2023-03-06 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On February 28, 2023, shareholders holding approximately 50.58% of the outstanding common stock of Immune Therapeutics, Inc. (the “Company”) executed a written consent (the “Written Consent”) in lieu of a special meeting of the shareholders approving an amendment to the amended and restated articles of incorporation of the Company to change the Company’s name to “Biostax Corp.” (the “Articles of Amendment”). | form8-k.htm |
| 2023-01-03 | 8-K | 2023-01-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 15, 2022, Kevin Phelps, a director of the Company, delivered a letter of resignation to the Company, pursuant to which Mr. Phelps resigned from his position as a director of the Company, effective December 31, 2022. | form8-k.htm |
| 2022-11-09 | 8-K | 2022-11-03 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 5.02 On November 3, 2022, Stephen Wilson, President, Chief Executive Officer, and a director of the Company, delivered a letter of resignation to the Company, pursuant to which Dr. Wilson resigned from all positions with the Company, effective immediately. 8.01 On November 9, 2022, the Company issued a press release announcing the appointment of Kelly O. Wilson as the Company’s Interim Chief Executive Officer and Interim President, Dr. Stephen Wilson’s resignation as the Company’s Chief Executive Officer, President and director, and Dr. Clifford Selsky’s resignation as a director of the Company. | form8-k.htm |
| 2022-10-12 | 8-K | 2022-10-12 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | form8-k.htm |
| 2022-09-27 | 8-K | 2022-09-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On September 20, 2022, the Board of Directors (the “Board”) of Immune Therapeutics, Inc. (the “Company”), resolved to increase the size of the Board from five to six members and appoint H. Louis Salomonsky to the Board to fill the vacancy created by such increase, both effective as of September 20, 2022. 8.01 On September 27, 2022, the Company issued a press release announcing the appointment of Mr. Salomonsky to the Board. | form8-k.htm |
| 2022-08-04 | 8-K | 2022-08-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On August 2, 2022, the board of directors of Immune Therapeutics, Inc. (the “Company”) appointed Mr. Glen Farmer, age 53, as the new Chief Financial Officer of the Company. 8.01 On August 4, 2022, Immune Therapeutics, Inc. (the “Company”) issued a press release announcing the resignation of Dr. Stephen Wilson as the Company’s interim Chief Financial Officer and appointment of Mr. Glen Farmer as the Company’s Chief Financial Officer to replace Dr. Wilson in that role. | form8-k.htm |
| 2022-07-22 | 8-K | 2022-07-18 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 The matters described in Section 1.01 of this Current Report on Form 8-K are incorporated herein by reference. 5.02 The matters described in Section 1.01 of this Current Report on Form 8-K are incorporated herein by reference. 8.01 On July 22, 2022, the Company issued a press release announcing the appointment of Dr. Stephen Wilson as the Company’s Chief Executive Officer, President, and interim Chief Financial Officer, and announcing Kevin Phelps’s resignation as the Company’s Chief Executive Officer, President, and Chief Financial Officer. | ea163189-8k_immune.htm |
| 2022-07-07 | 8-K | 2022-07-06 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 On June 29, 2022, the holders of certain warrants to purchase shares of common stock of the Company $0.0001 par value per share (“Common Stock”) of Immune Therapeutics, Inc., a Florida corporation (the “Company”) agreed to exercise their warrants at a price of five cents ($0.05) per share, resulting in $425,000 in proceeds to the Company (the “Warrant Exercises”). | form8-k.htm |
| 2022-06-03 | 8-K | 2022-06-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 (d) Election of Directors. 7.01 The issuer has filed a lawsuit in the United States District Court for the Eastern District of Virginia (Immune Therapeutics, Inc. v. Handley, case number 3:22-cv-00412-REP) against Michael K. Handley, the former CEO, President, and Director of the Issuer, and the current CEO and Director of Statera BioPharma Inc. The Issuer is a shareholder in Statera BioPharma Inc. A full copy of the complaint can be found at https://pacer.login.uscourts.gov/. | form8-k.htm |
| 2021-06-02 | 8-K | 2021-06-02 | 8.01 Other Events | 8.01 On May 25, 2021, Immune Therapeutics, Inc. (the “Company”) entered into a non-binding Letter of Intent with certain of the Company’s existing investors. | form8-k.htm |
| 2021-01-26 | 8-K | 2021-01-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 21, 2021, Michael Sander notified the Board of Directors of Immune Therapeutics, Inc. (the “Company”) of his resignation as a director of the Company, effective on January 21, 2021, to pursue other interests. | form8-k.htm |
| 2020-10-22 | 8-K | 2020-10-20 | 8.01 Other Events | 8.01 On October 20, 2020, the Company issued a press release announcing that Cytocom, Inc., a company in which the Company has significant shareholdings, and Cleveland BioLabs, Inc. entered into a definitive merger agreement. | form8-k.htm |
| 2020-08-18 | 8-K | 2020-08-16 | 1.01 Entry into a Material Definitive Agreement | 1.01 On August 16, 2020, Immune Therapeutics, Inc. (the “Company” or “Immune”) and Cytocom, Inc. (“Cytocom”) closed on an agreement for the Company to sublicense Lodonal (“LDN”) and Methionine Enkephalin (“MENK”) for emerging markets. | form8-k.htm |
| 2020-07-27 | 8-K | 2020-07-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 22, 2020, director Kevin J. Phelps, interim president and CEO of Immune Therapeutics, Inc. (“Immune” or the “Company”) entered into a three-year executive employment agreement (the “Agreement”) with the Company to serve as president and CEO. | form8-k.htm |
| 2020-05-14 | 8-K | 2020-05-14 | 8.01 Other Events | 8.01 On March 4, 2020, the U.S. Securities and Exchange Commission (the “SEC”) issued an order under Section 36 (Release No. 34-88318) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), granting exemptions from specified provisions of the Exchange Act and certain rules thereunder. | form8-k.htm |
| 2020-05-05 | 8-K | 2020-04-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 29, 2020, Mr. Michael K. Handley, director, president and CEO of Immune Therapeutics, Inc. (“Immune” or the “Company”) tendered his resignation in a letter to the Company’s Board, which was formally accepted on April 30, 2020. | form8-k.htm |
| 2020-04-16 | 8-K | 2020-02-27 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 8.01 Other Events | 1.01 On February 27, 2020, Immune Therapeutics Inc (the “Company”) approved and entered into a license agreement (the “License Agreement”) with Forte Biotechnology Intl Corp (“Forte”). 7.01 Immune has filed on March 30th, 2020 and received a 45-day extension under the new COVID19 policies at the SEC that allow companies additional time to for SEC filings due to the pandemic. 8.01 On April 16, 2020, the Company and Forte issued a joint press release announcing their entry into the License Agreement. | form8-k.htm |
| 2020-03-20 | 8-K | 2020-03-20 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 Effective as of March 17, 2020, the Immune Therapeutics, Inc., a Florida Company signed a binding letter of intent with a private company Cytocom, Inc that sets forth the preliminary terms and conditions of a potential collaboration agreement for the development of Lodonal™ and IRT-101 for use against COVID-19. 8.01 On March 20, 2020 Immune Therapeutics, Inc. issued a press release announcing a letter of intent that was signed with Cytocom, Inc. to develop Lodonal™ and other drugs for COVID-19. | form8-k.htm |
| 2020-02-19 | 8-K | 2020-02-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (d) On February 14, 2020 the Board of Directors of Immune Therapeutics Inc accepted the resignation of Edward Teraskiewicz. | form8-k.htm |
| 2019-10-31 | 8-K | 2019-10-25 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On October 25, 2018, Immune Therapeutics, Inc., a Florida corporation (the “Company” or “IMUN”) closed its voting by written consent as detailed in its Proxy Statement on form 14A, filed September 5, 2019 pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended (“Proxy Statement”). | form8-k.htm |
| 2019-09-25 | 8-K | 2019-09-20 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 On September 20, 2019, Immune Therapeutics, Inc., a Florida corporation (the “Company” or “IMUN”) entered into an Employment Agreement (the “Agreement”) with Michael K. Handley Pursuant to the Agreement, Mr. Handley agreed to serve as the Company’s Chief Executive Officer (“CEO”) and President. 5.02 On September 20, 2019, the Board accepted the resignation of Noreen Griffin as IMUN’s CEO and director. | form8-k.htm |
| 2019-07-01 | 8-K | 2019-05-30 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Immune Therapeutics, Inc., a Florida corporation (the “Company”), sent a Proxy Statement on Schedule 14A to shareholder of the Company on or around April 29, 2019 (the “Proxy Statement”). | form8-k.htm |
| 2019-05-15 | 8-K | 2019-05-15 | 8.01 Other Events | 8.01 Immune Therapeutics, Inc., a Florida corporation (the “Company”), sent a Proxy Statement on Schedule 14A to shareholders of the Company on or around April 29, 2019 (the “Proxy Statement”). | form8-k.htm |
| 2019-01-08 | 8-K | 2019-01-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 2, 2019, the directors of Immune Therapeutics, Inc., a Florida corporation (the “Company” or “IMUN”) appointed Kevin Phelps as a director to fill a vacancy on the Company’s Board of Directors. | form8-k.htm |
| 2018-06-11 | 8-K | 2018-06-04 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 8.01 Other Events | 1.01 On June 4, 2018, Immune Therapeutics, Inc., a Florida corporation (the “Company” or “IMUN”), entered into an amended and restated licensing agreement (the “Restated Agreement”) with Cytocom, Inc. (“Cytocom”). 2.01 See item 1.01 for the discussion of the Company’s acquisition of ten percent (10%) of the common stock of Cytocom, which is herein incorporated. 8.01 On June 5, 2018, the Company issued a press release announcing the execution of the Restated Agreement and the Stock Agreement. | form8-k.htm |
| 2018-05-22 | 8-K | 2018-04-17 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement | 1.01 On April 17, 2018, TNI BioTech International, Ltd. (“TNIB”), a subsidiary of Immune Therapeutics, Inc., a Florida corporation (the “Company”), effected a power of attorney (the “Power of Attorney”) which grants Fidson Healthcare Plc, a Nigerian company (“Fidson”) the authority to act on TNIB’s behalf in Nigeria with respects to Lodonal™, the Company’s lead drug candidate, including but not limited to submitting registration documents to regulatory authorities, following up on registration procedures, and all related other matters. 1.02 On October 2, 2013, the Company published a Form 8-K (the “2013 8-K”) announcing that TNIB had entered into a Distribution Agreement (the “AHAR Agreement”) with AHAR Pharma, a Nigerian company (“AHAR”), to market and distribute Lodonal™ in Nigeria. | form8-k.htm |
| 2018-04-27 | 8-K | 2018-04-26 | 8.01 Other Events | 8.01 On April 26, 2018, Immune Therapeutics, Inc., a Florida corporation (the “Company”) published a press release (the “Press Release”) announcing that the Kenya Pharmacy and Poison Board filed the Company’s New Drug Application (“NDA”) for Lodonal™, its lead drug candidate, thereby accepting the NDA for a full review. | form8-k.htm |
| 2018-03-28 | 8-K | 2018-03-26 | 8.01 Other Events | 8.01 On March 26, 2018, Immune Therapeutics, Inc., a Florida corporation (the “Company”) published a press release (the “Press Release”) announcing that it received minutes from the Type C meeting held on January 16, 2018, between the Company on behalf of Cytocom, Inc., the license holder, and the US Food and Drug Administration to discuss next steps in the development of IRT-103 “Lodonal”™, an oral once-a-day adjunct therapy to the standard of care for moderate to severe Crohn’s disease in adults and mild to severe in pediatric patients. | form8-k.htm |
| 2017-12-29 | 8-K | 2017-12-05 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 Please see Item 1.01 for discussion of the Options and the Warrants, which is incorporated herein by reference. 3.02 Please see Item 1.01 for discussion relating to the issuances of restricted shares, Warrants and Options to CSJ, ABS, and August Strategic and their assigns, which is incorporated herein by reference. | form8-k.htm |
| 2017-12-01 | 8-K | 2017-11-30 | 7.01 Regulation FD Disclosure | 7.01 On November 30, 2017, Immune Therapeutics, Inc. (the “Company”) issued a letter to update its shareholders on the Company’s recent progress and its objectives for 2018. | form8-k.htm |
| 2017-11-02 | 8-K | 2017-10-12 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 Please see Item 1.01 for discussion of the Note, which is incorporated herein by reference. 3.02 Please see Item 1.01 for discussion relating to issuance of the Warrant and Origination Shares, which is incorporated herein by reference. | form8-k.htm |
| 2017-09-08 | 8-K | 2017-08-22 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On September 6, 2017, Immune Therapeutics, Inc., a Florida corporation (the “Company”) issued a press release announcing that it has entered into the Agreement with Omaera for the sale and distribution of Lodonal™, valued at a minimum of $31 million in revenues over three years. | form8-k.htm |
| 2017-08-25 | 8-K | 2017-08-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 Immune Therapeutics, Inc. (the “Company”) has appointed Mr. Rudy Williams to serve as its Chief Operations Officer. 8.01 On August 24, 2017, the Company issued a press release announcing that its majority owned subsidiary, Cytocom, Inc., has appointed Dr. John Abeles as its Chairman, Director and CEO. | form8-k.htm |
| 2017-06-12 | 8-K | 2017-06-07 | 7.01 Regulation FD Disclosure | 7.01 On June 7, 2017, management of Immune Therapeutics, Inc., a Florida corporation (the “Company”) gave a presentation related to the business and performance of the Company at LD Micro 7th Annual LD Micro Invitational Conference at the Luxe Sunset Bel Air in Los Angeles. | form8-k.htm |
| 2017-05-23 | 8-K | 2017-05-22 | 8.01 Other Events | 8.01 On May 22, 2017, Immune Therapeutics, Inc., a Florida corporation (the “Company”) issued a press release announcing that it has received NAFDAC (National Agency for Food and Drug Administration and Control) approval to market and distribute LodonalTM in Nigeria. | form8-k.htm |
| 2017-05-09 | 8-K | 2017-05-01 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 On May 1, 2017 (“Effective Date”), Immune Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (“SPA”) with Ira Gaines (“Investor”). 3.02 Please see Item 1.01, incorporated herein by reference, for discussion relating to the issuance of shares pursuant to the SPA and the Warrant. | form8-k.htm |
| 2017-04-28 | 8-K | 2017-04-25 | 8.01 Other Events | 8.01 On April 25, 2017, Immune Therapeutics, Inc., a Florida corporation (the “Company”) issued a press release announcing that it has submitted its New Drug Application (“NDA”) to the Pharmacy and Poison Board (“PPB”) in Kenya for LodonalTM, for the treatment of patients with HIV and cancer, both as a standalone treatment as well as an adjunct treatment, and as an immunomodulator. | form8-k.htm |
| 2017-04-13 | 8-K | 2017-04-04 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 On or around April 4, 2017, Immune Therapeutics, Inc. (the “Company”) entered into a settlement agreement (the “Settlement Agreement”) with Mr. Marshall Faulk (“Faulk”). 2.03 Please see Item 1.01 Debt Purchase and Exchange Agreement, incorporated herein by reference, for discussion relating to the Note, which was issued by the Company on or around April 5, 2017. 3.02 Please see Item 1.01 Settlement Agreement, incorporated herein by reference, for discussion relating to the issuance of 2,000,000 restricted shares to Marshall Faulk. 8.01 On April 12, 2017, the Company issued a press release in the form attached hereto as Exhibit 99.1 regarding the foregoing. | form8-k.htm |
| 2017-03-20 | 8-K | 2017-03-17 | 8.01 Other Events | 8.01 On March 17, 2017, Immune Therapeutics, Inc., a Florida corporation (the “Company”) issued a press release announcing that the Dominican Republic Ministry of Public Health has granted the Company’s request to export Lodonal to Kenya. | form8-k.htm |
| 2017-03-17 | 8-K/A | 2017-02-07 | 8.01 Other Events | 8.01 On March 15, 2017, the Company issued a press release related to the foregoing. | form8-ka.htm |
| 2017-03-14 | 8-K | 2017-02-07 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement; 7.01 Regulation FD Disclosure; 8.01 Other Events | 1.01 On February 7, 2017, the Board of Directors of Immune Therapeutics, Inc. (the “Company”) approved a promissory note (“Note”) issued by the Company to Phoenix Fund Management, LLC (“PFM”) on February 6, 2017. 2.03 Please see Item 1.01, incorporated herein by reference, for discussion relating to the Note. 2.04 Prior to February 28, 2017, PFM demanded payment in full of the Note, which the Company failed to timely pay. 7.01 On January 30, 2017, Immune Therapeutics, Inc. (the “Company”) held a conference call with its shareholders to discuss financial highlights and operational outlook for 2017. 8.01 The Company strengthened its balance sheet through the refinancing of its largest outstanding note at $321,846, through using Note proceeds to pay off all of the Company’s debt to St. George Investments, LLC. | form8-k.htm |
| 2016-12-23 | 8-K | 2016-12-21 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 On December 21, 2016, Immune Therapeutics, Inc. (the “Company”) entered into an exchange agreement (the “Agreement”) with St. George Investments, LLC (“St. George”), whereby the Company agreed to exchange that certain promissory note issued by the Company to St. George on May 5, 2016 (the “Note”) for a substantially similar promissory note (the “Exchange Note”) and 700,000 free-trading shares of the Company’s common stock pursuant to 3(a)(9) of the Securities Act of 1933. 2.03 See disclosures in Item 1.01, which are incorporated by reference. | form8-k.htm |
| 2016-12-14 | 8-K | 2016-12-07 | 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement | 2.04 On December 7, 2016, Immune Therapeutics, Inc. (the “Company”) received a notice via email from St. George Investments, LLC (“St. George”) that the Company is in default of that certain promissory note (the “Note”), dated May 5, 2016, between St. George and the Company in the principal amount of $305,000. | form8-k.htm |
| 2016-11-15 | 8-K | 2016-11-04 | 8.01 Other Events | 8.01 On November 4, 2016, Immune Therapeutics, Inc. (the “Company”) paid off its Promissory Note with JMJ Financial, disclosed in the Current Form 8K/A filed by the Company on May 4, 2016, in the principal amount of $656,250. | form8-k.htm |
| 2016-11-15 | 8-K/A | 2016-10-25 | 1.01 Entry into a Material Definitive Agreement | 1.01 On October 25, 2016 Immune Therapeutics, Inc. and Acromax Dominicana, SA entered into a five year contract for manufacturing of LDN tablets, capsules and/or creams. | form8-ka.htm |
| 2016-11-02 | 8-K | 2016-10-25 | 1.01 Entry into a Material Definitive Agreement | 1.01 On October 25, 2016 Immune Therapeutics, Inc. and Acromax Dominicana, SA entered into a five year contract for manufacturing of LDN tablets, capsules and/or creams. | form8-k.htm |
| 2016-08-30 | 8-K | 2016-08-25 | 8.01 Other Events | 8.01 On August 25, 2016, Immune Therapeutics, Inc. notified warrant holders that have current warrants with an exercise price of $1.00 that their warrants have been extended until December 31, 2018 pursuant to board action. | form8-k.htm |
| 2016-08-23 | 8-K | 2016-08-23 | 8.01 Other Events | 8.01 On August 23, 2016, the Company issued a press release in the form attached hereto as Exhibit 99.1 related to funding for a clinical trial in Malawi. | form8-k.htm |
| 2016-07-26 | 8-K | 2016-07-26 | 8.01 Other Events | 8.01 On July 26, 2016, the Company issued a press release in the form attached hereto as Exhibit 99.1 related to an informational shareholder meeting for Immune Therapeutics, Inc. to be held on August 17, 2016 at 10 a.m. at the Citrus Club located at 255 South Orange Ave, Suite 1800, Orlando, FL 32801. | form8-k.htm |
| 2016-05-20 | 8-K | 2016-05-16 | 8.01 Other Events | 8.01 On May 16, 2016 Immune Therapeutics, Inc. (the “Company”) and Complete Pharmacy and Medical Solutions, LLC entered into a three year contract for compounding of the Company’s pharmaceutical products. | form8-k.htm |
| 2016-05-13 | 8-K | 2016-05-09 | 8.01 Other Events | 8.01 On May 9, 2016 Immune Therapeutics, Inc. (the “Company”) and KRS Global Bio Technology, Inc. mutually agreed to terminate their contract for compounding pharmaceutical products. | form8-k.htm |
| 2016-05-04 | 8-K/A | 2016-04-12 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry Into A Material Definitive Agreement Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. | form8-k.htm |
| 2016-04-27 | 8-K | 2016-04-27 | 8.01 Other Events | 8.01 On April 27, 2016, the Company issued a press release in the form attached hereto as Exhibit 99.1 related to NAFDAC Approval of Lodonal in Nigeria. | form8-k.htm |
| 2016-04-21 | 8-K | 2016-04-20 | 8.01 Other Events | 8.01 On April 20, 2016 Immune Therapeutics, Inc. (the “Company”) through its wholly owned subsidiary TNI BioTech International a BVI Corporation entered into a Binding Letter of Intent (“LOI”) with Super T-Cell Cancer Co., LTD (“Licensor”) a BVI Corporation. | form8-k.htm |
| 2016-04-18 | 8-K | 2016-04-12 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry Into A Material Definitive Agreement Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. | form8-k.htm |
| 2016-04-13 | 8-K | 2016-04-11 | 8.01 Other Events | 8.01 On April 11, 2016, the Company issued a press release in the form attached hereto as Exhibit 8.1. | form8-k.htm |
| 2016-03-16 | 8-K | 2016-02-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On February 29, 2016, Immune Therapeutics, Inc. (the “Company”) appointed two new directors, Clifford A. Selsky, Ph.D., MD, and Paul Akin, to fill vacancies on its board of directors. 8.01 On March 3, 2016, the Company issued a press release in the form attached hereto as Exhibit 8.01. | imun_8k.htm |
| 2016-01-06 | 8-K | 2015-12-29 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Entry into a Material Definitive Agreement. 5.02 On December 29, 2015, Mr. Saiid Zarrabian resigned from the Board of Directors of the Company. | imun_8k.htm |
| 2015-12-04 | 8-K | 2014-10-20 | 9.01 Financial Statements and Exhibits | imun_8k.htm | |
| 2015-11-20 | 8-K | 2015-11-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 15, 2015, Mr. Eugene Youkilis resigned from the board of directors of Immune Therapeutics, Inc. (the “Company”). | imun_8k.htm |
| 2015-10-08 | 8-K | 2015-10-01 | 8.01 Other Events | 8.01 On October 7, 2015, the Company issued a press release in the form attached hereto as Exhibit 8.1. | tnib_8k.htm |
| 2015-09-25 | 8-K | 2015-09-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 21, 2015, Immune Therapeutics, Inc. (the “Company”) appointed Mr. Saiid Zarrabian to serve on its Board of Directors. | tnib_8k.htm |
| 2015-06-22 | 8-K | 2015-06-16 | 1.02 Termination of a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On June 16, 2015, our board of directors (i) removed Mr. Seth Elliott from his positions of President and Chief Operating Officer of Immune Therapeutics, Inc., (ii) removed Mr. Vincent Butta as a member of our board of directors, and (iii) in connection with such removals, approved the termination of the Consulting Agreement between The Sevin Group, LLC and us, effective December 17, 2014 (the “Agreement”). | tnib_8k.htm |
| 2015-05-21 | 8-K | 2015-05-15 | 1.01 Entry into a Material Definitive Agreement | tnib_8k.htm | |
| 2015-01-26 | 8-K | 2015-01-21 | 8.01 Other Events | 8.01 ClearTrust, LLC is our new transfer agent and shareholder provider. | immune8k.htm |
| 2015-01-22 | 8-K/A | 2015-01-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Immune Therapeutics, Inc. (the “Company”) is filing this Form 8-K/A to correct an error contained in its Current Report on Form 8-K which was filed with the Securities and Exchange Commission on January 14, 2015 (the “Current Report”). | immune8ka.htm |
| 2015-01-20 | 8-K | 2015-01-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 The Board of Directors of Immune Therapeutics, Inc. (the “Company”), to fill a vacancy on the Board, has appointed Vincent Butta to serve as a director until the next annual meeting of the Company’s shareholders and his successor is elected and qualified or, if earlier, until his resignation or removal. | imun8k.htm |
| 2015-01-14 | 8-K | 2015-01-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective January 13, 2015, Dr. Eugene Youkilis is stepping down from the position of President of Immune Therapeutics, Inc. (the “Company”), but will continue to serve as a member of the Board of Directors of the Company. | immune8k.htm |
| 2014-12-15 | 8-K | 2014-12-08 | 1.01 Entry into a Material Definitive Agreement | immune8k.htm | |
| 2014-12-04 | 8-K | 2014-12-04 | 8.01 Other Events | tnib8k.htm | |
| 2014-10-30 | 8-K | 2014-10-20 | 1.01 Entry into a Material Definitive Agreement | tnib_8k.htm | |
| 2014-09-09 | 8-K | 2014-09-04 | 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 5.07 (a) On September 4, 2014, TNI BioTech, Inc. (the “Company”) held its 2014 Annual Meeting of Shareholders at the Citrus Club, 255 South Orange Avenue, Suite 1800, Orlando, Florida 32801 (the “Annual Meeting”). 8.01 On September 9, 2014, the Company issued a press release announcing the completion and the results of the Annual Meeting. | tnib8k.htm |
| 2014-08-13 | 8-K | 2014-08-06 | 1.01 Entry into a Material Definitive Agreement | tnib8k.htm | |
| 2014-06-25 | 8-K | 2014-06-11 | 1.01 Entry into a Material Definitive Agreement | tnib8k.htm | |
| 2014-05-07 | 8-K | 2014-05-01 | 8.01 Other Events | 8.01 On May 1, 2014, TNI Biotech, Inc. (the “Company”) issued a press release announcing the approval by its board of directors to spin-off its wholly-owned subsidiary, Cytocom, Inc. A copy of the press release is attached hereto as Exhibit 99.1. | tnib_8k.htm |
| 2013-10-02 | 8-K | 2013-09-17 | 1.01 Entry into a Material Definitive Agreement | 1.01 TNI BioTech International, Ltd., a wholly-owned subsidiary of TNI BioTech, Inc. (together, the “Company” or “TNIB”) executed a Distribution Agreement effective September 17, 2013 with AHAR Pharma, a company formed under the laws of the Federal Republic of Nigeria (the “Distributer”). | tnib_8k.htm |
| 2013-09-25 | 8-K | 2013-09-19 | 8.01 Other Events | 8.01 TNI BioTech, LTD, a subsidiary of TNI BioTech, Inc. (the “Company”), received approval to be considered an enterprise micro, small or medium-sized enterprise (“SME”) with the European Medicines Agency (“EMA”) on August 21, 2013. | tnib_8k.htm |
| 2013-09-12 | 8-K | 2013-09-06 | 3.02 Unregistered Sales of Equity Securities | 3.02 Since the beginning of the third quarter on July 1, 2013 through September 6, 2013, various warrant holders purchased an aggregate total of 1,652,500 shares of TNI BioTech, Inc. (the “Company”) at an exercise price of $.50 per share. | tnib_8k.htm |
| 2013-09-05 | 8-K | 2013-08-16 | 1.01 Entry into a Material Definitive Agreement | 1.01 TNI BioTech, Inc. (the “Company” or “TNI”) executed a manufacturing agreement with Laboratorios Ramos, S.A. (“Laboratorios Ramos”), a current good manufacturing practice (“cGMP”) facility, for IRT-103 LDN effective August 16, 2013. | tnib_8k.htm |
| 2013-08-21 | 8-K | 2013-08-21 | 8.01 Other Events | 8.01 TNI BioTech, Inc. (the “Company”), a Florida corporation, formed its United Kingdom subsidiary, TNI BioTech, LTD (the “Subsidiary”) on August 6, 2013. | tnib_8k.htm |
| 2013-07-26 | 8-K | 2013-07-17 | 8.01 Other Events | 8.01 On July 17, 2013 TNI BioTech, Inc. (“TNIB” or the “Company”) received the minutes from the June 26, 2012 meeting with the U.S. Food and Drug Administration (“FDA”) Division of Gastroenterology and Inborn Errors Products. | tnib_8k.htm |
| 2013-07-09 | 8-K | 2013-07-01 | 8.01 Other Events | 8.01 The U.S. Food and Drug Administration (“FDA”) has agreed to an End of Phase 2 meeting with TNI BioTech, Inc. (“TNIB” or the “Company”) on August 20, 2013 to discuss the Company’s clinical development program and Chemistry and Manufacturing Control (“CMC”) plans for Met-enkephalin (“MENK”) in combination with gemcitabine in the treatment of pancreatic cancer. | tni_8k.htm |
| 2013-06-07 | 8-K | 2013-05-28 | 8.01 Other Events | 8.01 TNI BioTech Inc. (the “Company”) issued a press release on Friday, June 7, 2013, stating that effective as of the opening of business on Monday, June 10, 2013, the Company will require the mandatory exchange of all existing common stock certificates issued under any prior CUSIP number for new stock certificates with the new CUSIP number: 872608203. | tnib_8k.htm |
| 2013-06-03 | 8-K | 2013-06-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Dr. Ronald Herberman, TNI BioTech Inc.'s (“TNIB” or the “Company”) Senior Vice President of Research and Development and Chief Medical Officer, unexpectedly passed away on Saturday, June 1, 2013, at the age of 72. | tnib_8k.htm |